Shandong Sinobioway Biomedicine Co Ltd

The company's capital structure is characterized by a low debt-to-equity ratio of 0.04, indicating a conservative leverage position. However, the company has negative operating and free cash flows, with operating cash flow at -253.73 million CNY and free cash flow at -303.19 million CNY, suggesting liquidity constraints. The current ratio of 3.3 indicates that the company has sufficient current assets to cover its current liabilities, but the negative net cash position after subtracting total debt raises concerns about short-term liquidity. Profitability metrics show a challenging financial position, with a return on equity (ROE) of -6.31% and a return on assets (ROA) of -5.36%, both significantly below the industry median for pharmaceutical companies. The company reported a net loss of 116.28 million CNY and an operating loss of 171.83 million CNY, indicating a lack of operational profitability. The company's revenue is concentrated in a single geographic market, primarily China, with no disclosed international revenue segments. This concentration increases exposure to local economic and regulatory risks. No segment-specific revenue breakdown is available in the provided data. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. Historical revenue data shows a total of 274.81 million CNY in the latest period, but no year-over-year growth rate is disclosed. The negative operating and net income suggest that the company is not currently generating sustainable earnings. Risk factors include medium liquidity risk due to negative operating and free cash flows, and a negative net cash position. The company has a low dilution risk, with no significant dilution potential reported. However, the negative net income and operating cash flow could pressure the company to raise additional capital, potentially leading to future dilution. Recent events include the latest financial filing, which discloses the company's negative operating and net income, as well as its liquidity position. No recent earnings call transcripts or other material events are provided in the available data.